SI1838318T1 - Uporaba oksikodona za zdravljenje visceralne bolečine - Google Patents

Uporaba oksikodona za zdravljenje visceralne bolečine

Info

Publication number
SI1838318T1
SI1838318T1 SI200630538T SI200630538T SI1838318T1 SI 1838318 T1 SI1838318 T1 SI 1838318T1 SI 200630538 T SI200630538 T SI 200630538T SI 200630538 T SI200630538 T SI 200630538T SI 1838318 T1 SI1838318 T1 SI 1838318T1
Authority
SI
Slovenia
Prior art keywords
oxycodone
visceral pain
treating visceral
treating
pain
Prior art date
Application number
SI200630538T
Other languages
English (en)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1838318(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of SI1838318T1 publication Critical patent/SI1838318T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
SI200630538T 2005-01-18 2006-01-17 Uporaba oksikodona za zdravljenje visceralne bolečine SI1838318T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
EP06700652A EP1838318B1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
SI1838318T1 true SI1838318T1 (sl) 2010-02-26

Family

ID=35871217

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200630538T SI1838318T1 (sl) 2005-01-18 2006-01-17 Uporaba oksikodona za zdravljenje visceralne bolečine

Country Status (32)

Country Link
US (2) US20080200493A1 (sl)
EP (1) EP1838318B1 (sl)
JP (1) JP5049139B2 (sl)
KR (10) KR20120089710A (sl)
CN (1) CN101106996B (sl)
AP (1) AP2249A (sl)
AR (1) AR052880A1 (sl)
AT (2) ATE446092T1 (sl)
AU (1) AU2006207498B2 (sl)
BR (1) BRPI0606247A2 (sl)
CA (1) CA2595043C (sl)
CY (1) CY1109660T1 (sl)
DE (2) DE602006009899D1 (sl)
DK (2) DK1838318T3 (sl)
EA (1) EA013544B1 (sl)
ES (1) ES2333901T3 (sl)
HK (1) HK1107933A1 (sl)
HR (1) HRP20090679T1 (sl)
IL (1) IL184530A (sl)
ME (1) ME01066B (sl)
MX (1) MX2007007207A (sl)
MY (1) MY144471A (sl)
NO (1) NO338968B1 (sl)
NZ (1) NZ555852A (sl)
PL (1) PL1838318T3 (sl)
PT (1) PT1838318E (sl)
RS (1) RS51069B (sl)
SI (1) SI1838318T1 (sl)
TW (1) TWI432196B (sl)
UA (1) UA85471C2 (sl)
WO (1) WO2006077212A1 (sl)
ZA (1) ZA200705231B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
AU2008258596B2 (en) 2007-06-04 2013-02-14 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2265287B1 (en) 2008-03-04 2018-09-05 Teva Pharmaceuticals International GmbH Methods of treating chronic pain
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
EP2470207A1 (en) * 2009-08-28 2012-07-04 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
EA033109B1 (ru) 2011-05-20 2019-08-30 Олдербайо Холдингз Ллк Способы ингибирования, профилактики или лечения диареи и/или поддержания соответствующих уровней электролитов и жидкости в толстой кишке субъекта, подвергающегося связанному с диареей состоянию, с помощью антитела против cgrp или фрагмента антитела против cgrp
EA201891284A1 (ru) 2011-05-20 2018-11-30 Олдербайо Холдингз Ллк Композиции антител против cgrp и их применение
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
JP6568099B2 (ja) 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
JP2022516956A (ja) 2019-01-08 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 抗ｃｇｒｐ抗体を用いた頭痛の急性治療及び迅速治療

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
NO338968B1 (no) 2016-11-07
CA2595043A1 (en) 2006-07-27
EA013544B1 (ru) 2010-06-30
KR20220165797A (ko) 2022-12-15
IL184530A (en) 2015-01-29
AR052880A1 (es) 2007-04-11
US9271974B2 (en) 2016-03-01
KR20120089710A (ko) 2012-08-13
KR20210131450A (ko) 2021-11-02
CN101106996A (zh) 2008-01-16
CN101106996B (zh) 2013-10-23
CY1109660T1 (el) 2014-08-13
KR20080106991A (ko) 2008-12-09
AU2006207498A1 (en) 2006-07-27
AU2006207498B2 (en) 2009-11-19
DK1838318T3 (da) 2010-01-04
EP1838318B1 (en) 2009-10-21
UA85471C2 (ru) 2009-01-26
KR20190135557A (ko) 2019-12-06
ZA200705231B (en) 2008-06-25
EA200701541A1 (ru) 2008-02-28
DK200700207U3 (da) 2007-09-28
ES2333901T3 (es) 2010-03-02
KR20200128451A (ko) 2020-11-12
EP1838318A1 (en) 2007-10-03
US20080200493A1 (en) 2008-08-21
AP2249A (en) 2011-07-18
BRPI0606247A2 (pt) 2009-06-09
PT1838318E (pt) 2009-12-15
NZ555852A (en) 2010-01-29
DE202006019887U1 (de) 2007-07-26
KR20230170811A (ko) 2023-12-19
RS51069B (sr) 2010-10-31
DE602006009899D1 (de) 2009-12-03
KR20070100368A (ko) 2007-10-10
WO2006077212A1 (en) 2006-07-27
ATE446092T1 (de) 2009-11-15
KR20140091782A (ko) 2014-07-22
HRP20090679T1 (hr) 2010-01-31
JP2008526927A (ja) 2008-07-24
CA2595043C (en) 2013-11-19
DK200700207U1 (da) 2007-08-24
PL1838318T3 (pl) 2010-03-31
MY144471A (en) 2011-09-30
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
IL184530A0 (en) 2007-10-31
US20150190393A1 (en) 2015-07-09
ME01066B (me) 2012-10-20
TW200637554A (en) 2006-11-01
TWI432196B (zh) 2014-04-01
AT9895U1 (de) 2008-05-15
HK1107933A1 (en) 2008-04-25
JP5049139B2 (ja) 2012-10-17
NO20074174L (no) 2007-10-17
AP2007004057A0 (en) 2007-08-31

Similar Documents

Publication Publication Date Title
HK1107933A1 (en) Use of oxycodone for treating visceral pain
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
IL248204A0 (en) Combined treatment of tumors expressing 38cd
GB0610867D0 (en) Treatment of pain
IL193748A0 (en) Treatment of pain
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
IL188430A0 (en) Treatment of tumors
IL193460A0 (en) Compounds and methods for treatment of stroke
EP1838714A4 (en) METHODS OF TREATING PAIN
EP2049139A4 (en) TREATMENT OF TUMORS EXPRESSING RAS
EP1928452A4 (en) USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
IL201422A0 (en) Therapeutic agents useful for treating pain
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
ZA200802935B (en) Use of lactobacillus for treatment of autoimmune diseases
EP1867640A4 (en) MEANS FOR TREATING SOLID TUMORS
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
GB0610868D0 (en) Treatment of pain
ZA200904478B (en) Novel therapeutic use for treating leukaemia
IL188894A0 (en) Compounds for treatment of lipase-mediated diseases
EP1813271A4 (en) PREVENTIVE / THERAPEUTIC AGENT FOR VISCERAL PAIN
GB0616450D0 (en) Treatment of pain
GB0623740D0 (en) Treatment of disease
EP1878443A4 (en) THERAPEUTIC AGENT FOR NEUROPATHIC PAIN
GB0408521D0 (en) Treatment of sepsis